𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Global clinical trials: Challenges ahead

✍ Scribed by Stephen L. Hauser; S. Claiborne Johnston

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
49 KB
Volume
70
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The DINO trial – challenges for translat
The DINO trial – challenges for translation into clinical practice
✍ Carmel T. Collins; Robert A. Gibson; Maria Makrides πŸ“‚ Article πŸ“… 2011 πŸ› Wiley (John Wiley & Sons) 🌐 English βš– 122 KB

## Abstract Infants born prematurely require higher amounts of dietary docosahexaenoic acid (DHA) than can be supplied through current strategies. Increasing the DHA content of breast milk and formula while achievable may not be the most efficacious approach. A new approach is required that enables

On statistical analysis for placebo-chal
On statistical analysis for placebo-challenging designs in clinical trials
✍ Shein-Chung Chow; Jun Shao; Hsin-Tsung Ho πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 78 KB πŸ‘ 1 views

In clinical trials, appropriate designs are often chosen to address scientific/medical questions of particular interest to the investigator. For a chosen statistical design, however, standard statistical procedures may not be applicable owing to the nature of the design. In this paper we examine sta

Adalimumab safety in global clinical tri
Adalimumab safety in global clinical trials of patients with Crohn's disease
✍ Jean-FrΓ©dΓ©ric Colombel; William J. Sandborn; Remo Panaccione; Anne M. Robinson; πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 145 KB πŸ‘ 2 views

Background: Adalimumab, a fully human anti-tumor necrosis factor (anti-TNF) monoclonal antibody, is approved for the treatment of Crohn's disease (CD) in adults. We evaluated the overall safety profile of adalimumab in global clinical trials in patients with CD. Patients who participated in these tr